Table 1 The distinct role of targeting Dll4 in normal ovary and ovarian cancer

Blocking Dll4 in vivo in the primate ovary using an anti-Dll4 monoclonal antibody results in increased luteal angiogenesis and microvascular density.

[23]

Normal ovary

In marmosets, microvascular tree within each corpus luteum was a significant increase after anti-Dll4 treatments.

[23]

Inactivation Dll4 with the blocking antibody YW152F induces a mild disorganisation of follicular vasculature.

[21]

Ovarian cancer

Dll4 RNAi silencing in ovarian tumour cells inhibited angiogenesis. Pericyte coverage was significantly decreased in the group treated with mouse Dll4 siRNA.

[31]